Skip to main content

Table 2 Clinical characteristics by local recurrence versus non local recurrence

From: Predicting a local recurrence after breast-conserving therapy by gene expression profiling

Characteristic Non-local recurrence Local recurrence p a All
No. of patients 144 17   161
Tumor size T1/T2 86/58 (67%/33%) 12/5 (71%/29%) 0.46 98/63 (61%/39%)
pN0/pN+ 83/61 (58%/42%) 7/10 (41%/59%) 0.19 90/71 (56%/44%)
Grade I/II/III 41/47/56 (28%/33%/39%) 2/7/8 (12%/41%/47%) 0.16 43/54/64 (27/33/40%)
Age <40 years 28 (19%) 7 (41%) 0.074 35
Median follow-up (years) 7.68 9.31 0.014 7.69
Metastasis 40 (28%) 9 (53%) 0.004 49 (30%)
Chemotherapy 50 (35%) 8 (47%) 0.291 58 (36%)
Hormonal therapy 16 (11%) 2 (12%) 0.86 18 (11%)
ER+/ER- 109/35 (76%/24%) 12/5 (71%/29%) 0.42 121/40 (75%/25%)
Median RT dose (Gy) 50 50 0.47 50
Median boost dose (Gy) 15 15 0.22 15
Boost, yes/no 131/13 (91%/9%) 13/4 (76%/24%) 0.075 144/17 (89%/11%)
Margins infiltrating carcinomab 129, 6, 9 (90%, 4%, 6%) 16, 1, 0 (94%, 6%, 0%) 0.365 145, 7, 9 (90%, 4%, 6%)
Margins DCISc 49, 76, 9, 10 (34%, 53%, 6%, 7%) 3, 13, 1, 0 (18%, 76%, 6%, 0%) 0.65 52, 89, 10, 10 (33%, 55%, 6%, 6%)
  1. pN0, pathologically node negative; pN+, pathologically node positive; ER, estrogen receptor; RT, radiotherapy; DCIS, ductal carcinoma in situ.
  2. aCox univariate; bresults are given in the following sequence: radical, focally positive resection margin, extensively positive resection margin or positive resection margin not otherwise specified; cresults are given in the following sequence: no DCIS, radical, focally positive resection margin, extensively positive resection margin or positive resection margin not otherwise specified.
\